Use of Closed Loop Insulin Delivery for Glucose Control in Patients With Insulin Dependent Diabetes Mellitus After Kidney Transplantation

Type 1 Diabetes Clinical Trial

Official title:

Use of Closed Loop Insulin Delivery in the Immediate Postoperative Period Following Deceased Donor Kidney Transplant in Patients With Insulin Dependent Diabetes Mellitus

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04189510
• Other study ID #: 190055
• Status: Withdrawn
• Phase: N/A
• Start date: April 1, 2021
• Est. completion date: December 31, 2021

Study information

• Verified date: November 2021
• Source: University of Virginia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will be a prospective, single center, randomized controlled parallel group open-label trial. Participants with insulin requiring diabetes mellitus who have been offered an organ for living or deceased donor kidney transplantation will be recruited prior to transplantation surgery. Patients will be randomized in a 2:1 fashion to AP (6 patients) and conventional treatment groups (3 patients). At the end of the subject's post-operative in-patient stay, participants will have the option of wearing a blinded CGM at home for 4 weeks while treating themselves with multiple daily injections (MDI).

Description:

The purpose of this study is to conduct a hypothesis-generating pilot study to assess the efficacy and safety of the closed loop control in kidney transplant recipients with history of insulin requiring diabetes mellitus in the early postoperative period. This study will be a prospective, single center, randomized controlled parallel group open-label trial. Participants with insulin requiring diabetes mellitus who have been offered an organ for living or deceased donor kidney transplantation will be recruited prior to transplantation surgery. Patients will be randomized in a 2:1 fashion to AP (6 patients) and conventional treatment groups (3 patients). At the end of the subject's post-operative in-patient stay, participants will have the option of wearing a blinded CGM at home for 12 weeks while treating themselves with multiple daily injections (MDI).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age =18.0 years old at time of consent

2. History of insulin requiring diabetes mellitus, type 1 or type 2, who have end stage renal disease (ESRD)

3. Expected to undergo deceased or living donor kidney transplant surgery

4. History of insulin prescription (past or current use)

5. If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all females of childbearing potential. Participants who become pregnant will be discontinued from the study.

6. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already, and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the study

7. Total daily insulin dose (TDD) at least 10 U/day

8. An understanding and willingness to follow the protocol and signed informed consent

Exclusion Criteria:

1. Pregnancy or intent to become pregnant during the trial

2. Currently breastfeeding or planning to breastfeed

3. A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol.

4. Having a family member(s) employed by Tandem Diabetes Care, Inc. or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial.

5. Patients who have consented to participate in other interventional trials will be excluded or given the opportunity to exit from the study

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Diabetes Mellitus, Type 2
• End Stage Renal Disease (ESRD)
• Insulin-requiring Type 2 Diabetes Mellitus
• Kidney Failure, Chronic
• Type 1 Diabetes

Intervention

Device:
• Artificial Pancreas
The Artificial Pancreas will delivery insulin in place of Multiple Daily Injections after a kidney transplant.

Other:
• Multiple Daily Injections
Multiple Daily Injections as standard of care post kidney transplant.

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
University of Virginia	DexCom, Inc., Tandem Diabetes Care, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of Artificial Pancreas system	Safety will be assessed by using a continuous glucose monitor, which measures interstitial glucose concentrations every 5 minutes for 24 hours a day. We will measure percentage of time in 24 hour period that the continuous glucose monitor (CGM) measures interstitial glucose values <70 mg/dL per day as a surrogate assessment of safety.	5 Weeks
Primary	Efficacy of Artificial Pancreas system	Efficacy will be assessed by using a continuous glucose monitor, which measures interstitial glucose concentrations every 5 minutes, 24 hours per day. We will measure percentage of time in 24 hour period that the continuous glucose monitor (CGM) measures interstitial glucose values between 70-180 mg/dL as a surrogate assessment of efficacy.	5 Weeks